Table 1.
Patients Demographics and Clinical Characteristics
| Parameters | Overall Population (N = 42) | Efficacy Phase (N = 16) |
|---|---|---|
| Age (years) | 60.5 (51.7–64.9) (41/42) | 60.5 (52.7, 64.5) (15/16) |
|
| ||
| Sex (male) (%) | 79 (33/42) | 69 (11/16) |
|
| ||
| LA Size (mm) | 42.0 (38.5–46.0) (32/42) | 40.0 (38.0–43.0) (12/16) |
|
| ||
| LVEF (%) | 60.0 (58.5,−65.5) (36/42) | 62.5 (60.0–68.0) (14/16) |
|
| ||
| PAF Durations (months) | 40.2 (19.8–73.7) (32/42) | 57.0 (14.9–100.6) (12/16) |
|
| ||
| Beta Blocker Use | 57% (24/42)* | 69% (11/16) |
|
| ||
| AAD Use | 62% (26/42)* | 69% (11/16) |
| Class Ic | 38% (16/42)** | 44% (7/16) |
| Class III | 21% (9/42)** | 25% (4/16) |
Results are median (Q1-Q3) (n/N)
Abbreviations: LA: left atrial roof; LVEF: Left ventricular ejection fraction; PAF: Paroxysmal atrial fibrillation : AAD: Antiarrhythmic drug
*
1 patient had no Beta Blocker or AAD information entered
**
1 patient who reported AAD use did not have a class listed